Metraipolis › archive › dc_aeee8d615c4f

Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects — Europe PMC PMID:42170063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42170063
DOI
10.1016/j.prdoa.2026.100440
License (as archived)
solo-consultazione
Archived
2026-10-08T09:38:51.080Z
SHA-256 of the archived text
acd64c8840af9038f2304d13b1b40f59278d20cb91645614f58745d3ebf56bfb
Stable URL of this page
https://metraipolis.com/documento/dc_aeee8d615c4f

How to cite

Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects — Europe PMC PMID:42170063 — Europe PMC (en), https://europepmc.org/article/MED/42170063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_aeee8d615c4f (Metraipolis archive dc_aeee8d615c4f, sha256 acd64c8840af9038f2304d13b1b40f59278d20cb91645614f58745d3ebf56bfb)
BibTeX
@misc{dcaeee8d615c4f,
  title = {Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects — Europe PMC PMID:42170063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42170063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_aeee8d615c4f; sha256 acd64c8840af9038f2304d13b1b40f59278d20cb91645614f58745d3ebf56bfb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42170063. Agents can read the archived copy with the MCP tool read_document.